drugset / Trial / NCT00769041
A Thorough EKG Safety Study of TA-1790 (Avanafil)
RandomizedCrossoverDouble-blindTreatment
Summary
This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avanafil | Small molecule | 100 mg | — |
| Subject | Avanafil | Small molecule | 800 mg | — |
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |